Review of NICE Technology Appraisal Guidance No 65: The use of rituximab for the treatment of aggressive non-Hodgkin?s lymphoma

The Institute was proposing that the review date should be extended to August 2008 because of potential developments with regard to maintenance therapy in treatment of people with localised disease.

Following consultation, the majority of comments received have led to the decision that the proposal might not be the best way to proceed with the review. After consideration of all the comments, the Institute's Guidance Executive has decided that the guidance should be placed on the static list.

The list of static technology appraisal guidance will be updated accordingly.